Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CHKA | P35790 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464775 | 0.89 | ALDH1A1 (0.40) | ALDH1A1HTTCHKAKDM4ELTA4H | |
| SCHEMBL31464828 | 0.88 | ALDH1A1 (0.55) | ALDH1A1HTTHRH3CHKAKDM4E | |
| SCHEMBL30316025 | 0.87 | ALDH1A1 (0.57) | ALDH1A1HTTHRH3CHKAKDM4E | |
| SCHEMBL18953692 | 0.87 | ALDH1A1 (0.37) | ALDH1A1HTTCHKAKDM4E | |
| SCHEMBL19211664 | 0.86 | ALDH1A1 (0.45) | ALDH1A1HTTHRH3CHKAKDM4E | |
| SCHEMBL31533274 | 0.86 | HRH3 (0.45) | ALDH1A1HTTHRH3BRD4KDM4E | |
| SCHEMBL31464835 | 0.86 | CHKA (0.50) | ALDH1A1HTTCHKA | |
| SCHEMBL538831 | 0.86 | HRH3 (0.45) | ALDH1A1HTTHRH3BRD4KDM4E | |
| SCHEMBL31464575 | 0.82 | PKM (0.47) | ALDH1A1HTTCHKA | |
| SCHEMBL31464669 | 0.82 | ALDH1A1 (0.40) | ALDH1A1HTTCHKAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | ALDH1A1 4773/4885HTT 2254/4885SIGMAR1 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.